title: [A case of interstitial pneumonia induced by CPT-11 for local recurrence of rectal cancer].
abstract: A 60-year-old man underwent total pelvic exenteration for rectal cancer and urinary bladder invasion.He received adjuvant chemotherapy with S-1 and PSK.Because of local recurrence in the 4th postoperative month, he underwent FOLFIRI therapy followed by mFOLFOX6 therapy.After an adverse reaction occurred for OHP, CPT-11 therapy was performed.After 1 course of CPT-11 therapy, he complained of dyspnea and chest pain.We suspected drug-induced interstitial pneumonia, and stopped chemotherapy.He still complained dyspnea, and was treated with PSL.Once dyspnea improved, he gradually deteriorated and was admitted to the hospital.He was given oxygen and steroid pulse therapy, but died of respiratory failure.
authors.affiliation: Dept. of Surgery, Hasuda Hospital, Japan.
authors.forename: Eriko
authors.initials: E
authors.lastname: Katsuta
authors.forename: Jun
authors.initials: J
authors.lastname: Kaneko
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Someno
authors.forename: Morihito
authors.initials: M
authors.lastname: Saguchi
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Aoyagi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Taro
authors.initials: T
authors.lastname: Takahata
authors.forename: Kumi
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Setsuo
authors.initials: S
authors.lastname: Hamada
authors.forename: Shizuaki
authors.initials: S
authors.lastname: Maejima
mesh_terms: D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D006801:Humans; D000077146:Irinotecan; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D012008:Recurrence
chemical_list: D000077146:Irinotecan; D002166:Camptothecin